MX342921B - Nuevos complejos a base de iridio para electroquimioluminiscencia (ecl). - Google Patents

Nuevos complejos a base de iridio para electroquimioluminiscencia (ecl).

Info

Publication number
MX342921B
MX342921B MX2013008418A MX2013008418A MX342921B MX 342921 B MX342921 B MX 342921B MX 2013008418 A MX2013008418 A MX 2013008418A MX 2013008418 A MX2013008418 A MX 2013008418A MX 342921 B MX342921 B MX 342921B
Authority
MX
Mexico
Prior art keywords
ecl
based complexes
new iridium
complexes
iridium
Prior art date
Application number
MX2013008418A
Other languages
English (en)
Other versions
MX2013008418A (es
Inventor
Cysewski Robert
De Cola Luisa
Miguel Fernandez Hernandez Jesus
- Peter Josel Hans
Lopez - Calle Eloisa
Zarnt Toralf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013008418A publication Critical patent/MX2013008418A/es
Publication of MX342921B publication Critical patent/MX342921B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0033—Iridium compounds
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G55/00—Compounds of ruthenium, rhodium, palladium, osmium, iridium, or platinum
    • C01G55/002—Compounds containing, besides ruthenium, rhodium, palladium, osmium, iridium, or platinum, two or more other elements, with the exception of oxygen or hydrogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/30—Electrochemically active labels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Inorganic Chemistry (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a nuevos complejos luminiscentes a base de iridio Ir(III), a los conjugados que comprenden estos complejos como una etiqueta y a su aplicación, por ejemplo en la detección a base de la electroquimioluminiscencia de un analito.
MX2013008418A 2011-02-09 2012-02-07 Nuevos complejos a base de iridio para electroquimioluminiscencia (ecl). MX342921B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11153913 2011-02-09
PCT/EP2012/051996 WO2012107419A1 (en) 2011-02-09 2012-02-07 New iridium-based complexes for ecl

Publications (2)

Publication Number Publication Date
MX2013008418A MX2013008418A (es) 2013-09-13
MX342921B true MX342921B (es) 2016-10-19

Family

ID=44065590

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008418A MX342921B (es) 2011-02-09 2012-02-07 Nuevos complejos a base de iridio para electroquimioluminiscencia (ecl).

Country Status (12)

Country Link
US (2) US8835637B2 (es)
EP (1) EP2673284B1 (es)
JP (1) JP5786040B2 (es)
KR (1) KR20140053834A (es)
CN (1) CN103347888B (es)
AU (1) AU2012215497B2 (es)
BR (1) BR112013019503B1 (es)
CA (1) CA2822899A1 (es)
ES (1) ES2645765T3 (es)
MX (1) MX342921B (es)
SG (1) SG192675A1 (es)
WO (1) WO2012107419A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104769077B (zh) * 2012-08-02 2017-08-08 霍夫曼-拉罗奇有限公司 用于ecl的新型铱基配合物
JP6255017B2 (ja) * 2012-08-02 2017-12-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｅｃｌ用の新規イリジウムベース錯体
ES2602206T3 (es) 2012-08-02 2017-02-20 F. Hoffmann-La Roche Ag Nuevos complejos de bis-iridio para la elaboración de marcajes EQL
KR101520527B1 (ko) * 2012-11-21 2015-05-14 주식회사 두산 이리듐(ⅲ) 착화합물 및 이를 포함하는 유기 전계 발광 소자
JP5818870B2 (ja) * 2012-12-27 2015-11-18 キヤノン株式会社 有機発光素子及び表示装置
JP6071569B2 (ja) * 2013-01-17 2017-02-01 キヤノン株式会社 有機発光素子
JP6222931B2 (ja) * 2013-01-21 2017-11-01 キヤノン株式会社 有機発光素子
JP5984689B2 (ja) 2013-01-21 2016-09-06 キヤノン株式会社 有機金属錯体及びこれを用いた有機発光素子
EP3353201B1 (en) 2015-09-25 2021-09-08 F. Hoffmann-La Roche AG Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
EP3208260A1 (en) * 2016-02-17 2017-08-23 Clariant International Ltd Alkoxylated hydroxybenzoic acid esters or amides
JP7080176B2 (ja) 2016-02-29 2022-06-03 エフ．ホフマン－ラ ロシュ アーゲー 子癇前症におけるマーカーとしてのｉｇｆｂｐ－７
ES2974284T3 (es) 2016-03-11 2024-06-26 Roche Diagnostics Gmbh Aminas de cadena ramificada en la detección de electroquimioluminiscencia
US10231639B2 (en) 2016-04-19 2019-03-19 Roche Diagnostics Operations, Inc. Algorithm of NTproBNP and hand held ECG to detect arrhythmia in an elderly population
EP3472622B1 (en) * 2016-06-17 2020-08-05 Roche Diagnostics GmbH Circulating angiopoietin-2 (ang-2) for the prediction of recurrence of atrial fibrillation
EP3279665B1 (en) 2016-08-04 2020-07-08 Roche Diagniostics GmbH Circulating esm-1 (endocan) in the assessment of atrial fibrillation
BR112019003709A2 (pt) 2016-08-25 2019-05-28 Centre Nat Rech Scient nanopartículas de silício multifuncionalizadas, usos de nanopartículas de silício multifuncionalizadas, composição e métodos para medir um analito por um método in vitro
JP6977058B2 (ja) 2017-04-12 2021-12-08 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ピクテ・スペングラー反応を介して得られたタグ付けヌクレオシドを用いたシーケンシング反応のための方法
KR102356418B1 (ko) 2017-06-13 2022-02-08 에프. 호프만-라 로슈 아게 심방 세동 (af) 의 평가를 위한 지방산 결합 단백질 3
KR20200027522A (ko) 2017-07-13 2020-03-12 에프. 호프만-라 로슈 아게 Pivka에 대한 신규 결합제 및 어세이
JP7403444B2 (ja) 2017-10-20 2023-12-22 エフ． ホフマン－ラ ロシュ アーゲー 抗体の複写保護措置
CN111480081A (zh) 2017-12-13 2020-07-31 豪夫迈·罗氏有限公司 用于预测脑卒中的循环血管生成素-2(Ang-2)和胰岛素样生长因子结合蛋白7(IGFBP7)
KR20200133229A (ko) 2018-03-14 2020-11-26 에프. 호프만-라 로슈 아게 신규한 항-트로포닌 t 항체
BR112020018235A2 (pt) 2018-03-14 2020-12-29 F. Hoffmann-La Roche Ag Métodos para gerar uma biblioteca de polinucleotídeos, bibliotecas de polinucleotídeos, uso de uma biblioteca, método para gerar uma biblioteca de anticorpos e método de seleção de um anticorpo
JP2021522192A (ja) 2018-04-18 2021-08-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規抗チミジンキナーゼ抗体
CN112673259A (zh) 2018-07-20 2021-04-16 豪夫迈·罗氏有限公司 基于igfbp-7的先兆子痫预测
CN113167799A (zh) 2018-07-31 2021-07-23 豪夫迈·罗氏有限公司 循环DKK3(Dickkopf相关蛋白3)在心房颤动评定中的应用
KR20210044216A (ko) 2018-08-10 2021-04-22 에프. 호프만-라 로슈 아게 심방세동-관련 뇌졸중 평가를 위한 ces-2 (카르복실에스테라제-2)
JP2021535370A (ja) 2018-08-16 2021-12-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 心房細動および抗凝固療法の評価における循環ｔｆｐｉ−２（組織因子経路阻害剤２）
CN113260863A (zh) 2018-08-17 2021-08-13 豪夫迈·罗氏有限公司 用于心房纤颤的评价中的循环bmp10 (骨形态发生蛋白10)
EP3841381A1 (en) 2018-08-22 2021-06-30 Roche Diagnostics GmbH Circulating spon-1 (spondin-1) in the assessment of atrial fibrillation
WO2020039085A1 (en) 2018-08-24 2020-02-27 Roche Diagnostics Gmbh Circulating fgfbp-1 (fibroblast growth factor-binding protein 1) in the assessment of atrial fibrillation and for the prediction of stroke
CN112639475A (zh) 2018-08-31 2021-04-09 豪夫迈·罗氏有限公司 Dlbcl的预后指数中的胸苷激酶(tk-1)
WO2020234451A1 (en) 2019-05-23 2020-11-26 Roche Diagnostics Gmbh IGFBP7 RATIO FOR HFpEF
WO2021013786A1 (en) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag S100a6 as blood biomarker for the non-invasive diagnosis of endometriosis
BR112022000945A2 (pt) 2019-07-22 2022-03-08 Hoffmann La Roche Métodos para avaliar se uma paciente tem endometriose ou está em risco de desenvolver endometriose, para selecionar uma paciente para terapia e para monitorar uma paciente que sofre de endometriose ou que está sendo tratada para endometriose
JP7315781B2 (ja) 2019-07-22 2023-07-26 エフ． ホフマン－ラ ロシュ アーゲー 子宮内膜症の非侵襲的診断のための血液バイオマーカーとしてのｓ１００ａ１２
CN114144674A (zh) 2019-07-22 2022-03-04 豪夫迈·罗氏有限公司 P物质作为用于子宫内膜异位症的非侵入性诊断的血液生物标志物
KR20220016210A (ko) 2019-07-22 2022-02-08 에프. 호프만-라 로슈 아게 자궁내막증의 비-침습적 진단용 혈액 생물표지자로써 s100a9
BR112022008068A2 (pt) 2019-10-28 2022-07-12 Hoffmann La Roche Métodos para auxiliar na avaliação de risco de um paciente com suspeita de sepse e método implementado por computador para a avaliação de um paciente com suspeita de sepse
EP4058459A1 (en) 2019-11-15 2022-09-21 F. Hoffmann-La Roche AG Derivatization of beta-lactam antibiotics for massspec measurements in patient samples
CN115190886A (zh) 2020-02-20 2022-10-14 马斯特里赫特大学 循环bmp10（骨形态发生蛋白10）的检测方法
CN115698721A (zh) 2020-03-18 2023-02-03 豪夫迈·罗氏有限公司 用于卒中的评估的ret（转染重排）
EP3943946A1 (en) 2020-07-20 2022-01-26 F. Hoffmann-La Roche AG Gdf-15 for predicting the disease severity of a patient with covid-19
JP2023537749A (ja) 2020-08-14 2023-09-05 エフ． ホフマン－ラ ロシュ アーゲー 無症候性脳梗塞及び認知低下の評価のためのｉｇｆｂｐ７
WO2022034162A1 (en) 2020-08-14 2022-02-17 F. Hoffmann-La Roche Ag Esm-1 for the assessment of silent brain infarcts and cognitive decline
CN116097098A (zh) 2020-08-14 2023-05-09 豪夫迈·罗氏有限公司 用于评定无症状脑梗死和认知衰退的多标志物组
JP2023550278A (ja) 2020-10-30 2023-12-01 エフ． ホフマン－ラ ロシュ アーゲー 胆管癌のマーカーとしてのｔｉｍｐ１
EP4237441A1 (en) 2020-11-02 2023-09-06 F. Hoffmann-La Roche AG Sars-cov-2 nucleocapsid antibodies
WO2022207628A1 (en) 2021-03-30 2022-10-06 F. Hoffmann-La Roche Ag Scf as blood biomarker for the non-invasive diagnosis of endometriosis
WO2022207685A1 (en) 2021-04-01 2022-10-06 F. Hoffmann-La Roche Ag Psp94 as blood biomarker for the non-invasive diagnosis of endometriosis
WO2022243210A1 (en) 2021-05-17 2022-11-24 F. Hoffmann-La Roche Ag sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS
WO2023072904A1 (en) 2021-10-26 2023-05-04 F. Hoffmann-La Roche Ag Monoclonal antibodies specific for sars-cov-2 rbd
WO2023083895A1 (en) 2021-11-10 2023-05-19 F. Hoffmann-La Roche Ag Hydrophilic azadibenzocyclooctyne derivatives and metal-free click reactions with these hydrophilic azadibenzocyclooctyne derivatives
WO2023111168A1 (en) 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag A novel antibody for detection of amyloid beta 42 (aβ42)
WO2023131594A1 (en) 2022-01-05 2023-07-13 F. Hoffmann-La Roche Ag Derivatization of compounds in patient samples for therapeutic drug monitoring (tdm)
WO2023247752A1 (en) 2022-06-23 2023-12-28 F. Hoffmann-La Roche Ag Method for diagnosing endometriosis and for classifying the stage of endometriosis
WO2024017985A1 (en) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Fibroblast growth factor binding protein 1 (fgfbp1) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome
WO2024017983A1 (en) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Meteorin-like protein (metrnl) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome
WO2024017982A1 (en) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Leukotriene a4 hydrolase (lta4h) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219847A (en) 1989-06-12 1993-06-15 Shiseido Company, Ltd. Antipruritic composition
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3650082B2 (ja) * 2001-06-04 2005-05-18 三洋電機株式会社 有機エレクトロルミネッセンス素子、発光材料および有機化合物
JP4496357B2 (ja) * 2004-06-04 2010-07-07 独立行政法人産業技術総合研究所 フッ素置換イリジウム錯体およびこれを用いた発光材料
JP4896512B2 (ja) * 2005-12-22 2012-03-14 昭和電工株式会社 高分子発光材料、有機エレクトロルミネッセンス素子および表示装置
CN101354352B (zh) * 2008-08-28 2010-08-25 江南大学 基于铱配合物电致化学发光法检测铵的传感器
CN101451954A (zh) * 2008-12-11 2009-06-10 复旦大学 一种定性检测半胱氨酸和高半胱氨酸的比度磷光化学传感器及其应用
CN101787054B (zh) * 2010-03-23 2013-04-17 上海师范大学 一种水溶性阳离子型铱配合物磷光探针及制备方法

Also Published As

Publication number Publication date
CA2822899A1 (en) 2012-08-16
KR20140053834A (ko) 2014-05-08
US8835637B2 (en) 2014-09-16
WO2012107419A1 (en) 2012-08-16
AU2012215497B2 (en) 2016-07-28
EP2673284A1 (en) 2013-12-18
ES2645765T3 (es) 2017-12-07
BR112013019503A2 (pt) 2020-11-10
JP2014506571A (ja) 2014-03-17
JP5786040B2 (ja) 2015-09-30
MX2013008418A (es) 2013-09-13
CN103347888B (zh) 2016-12-21
SG192675A1 (en) 2013-09-30
EP2673284B1 (en) 2017-08-30
US20130323719A1 (en) 2013-12-05
US20160145281A1 (en) 2016-05-26
CN103347888A (zh) 2013-10-09
AU2012215497A1 (en) 2013-07-04
BR112013019503B1 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
MX342921B (es) Nuevos complejos a base de iridio para electroquimioluminiscencia (ecl).
CL2013000028S1 (es) Conector
SG195196A1 (en) Dual targeting
IN2012DN06714A (es)
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
MY165002A (en) Cylodextrin complexation methods for formulating peptide proteasome inhibitors
GB201103836D0 (en) Conjugation process
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
IN2015MN00135A (es)
BR112013001033A2 (pt) processo de fabricação pela embalagem de injetáveis
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
MX349373B (es) Nuevos derivados de pirazina.
WO2014019709A3 (en) New iridium-based complexes for ecl
BRPI0914940A8 (pt) Composições nutritivas contendo punicalaginas
WO2014019707A3 (en) New iridium-based complexes for ecl
MX2016008183A (es) Polvo de carbon conductor, metodo para la fabricacion del mismo y uso del mismo.
CL2009001973S1 (es) Mostrador.
GEP201706708B (en) Isoxazolidine derivatives
PH12014502326A1 (en) A composition compromising amlodipine and losartan having an improved stability
MY170453A (en) Etching material
MX2015006616A (es) Doble direccion.
MX2014001920A (es) Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma.
AU338012S (en) Dinosaur costume
CL2011001069S1 (es) Triciclo.
UA45669U (en) Mixed-ligand complex compound of ytterbium (iii) with n-alkylsubstituted 2-aminobenzoic acids and 1,10-phenanthroline

Legal Events

Date Code Title Description
FG Grant or registration